BioProgress
www.bioprogress.comSymbol: MDX.L
Currently trading at: 11p UP 0.25
BioProgress plc develops and commercialises patents covering water soluble and biodegradable films, and process machinery, and has recently set up a new pharmaceutical division - Dexo BioPharm - that applies its technologies to products, develops new products and markets the enhanced products directly.
BioProgress Technology Ltd was founded in 1996 with the initial concept of producing materials to retire gelatin as the principal material used for the encapsulation of drugs, vitamins and other oils and powders. In 1997, BTL obtained a public listing for its shares by reversing into BioProgress Technology International, Inc (BTII).
BTII's shares were traded on the NASD OTC Bulletin Board in New York until May 2003, at which time BTII was acquired by BioProgress plc, which raised £5m through a placing with institutions and was admitted to the Alternative Investment Market of the London Stock Exchange.
BioProgress is entering the commercialisation phase of its patent-protected technology in the field of water soluble and biodegradable films. The company's principal product is the XGel Film System. XGel's primary aim is to retire gelatine from use in oral dose pharmaceuticals, as well as other products such as vitamins, minerals and supplements.
In addition to the XGel Film System, the company has developed other technologies and products including environmentally friendly feminine hygiene products and the first fully-biodegradable and flushable ostomy system for the healthcare market. BioProgress has also signed contracts with Procter and Gamble and Nestle relating to certain uses for XGel Film.
The company changed its name to Meldex International plc in Septmeber 2007.
Staff
 Richard Trevillion, Chief Executive OfficerRichard Trevillion joined the Board in February 2005. He is the founder, former CEO and a Non-Executive Director of Amity Partners Limited, a principal healthcare and technology finance business which has been responsible for numerous transactions since it was formed in late 2002. A qualified solicitor, Mr Trevillion began his career with law firms Lovell White Durrant and Simmons & Simmons, before moving to corporate finance where his senior experience includes being co-Director at Arthur Andersen responsible for their healthcare corporate finance team. Mr Trevillion then became Head of healthcare within the technology corporate finance group at Close Brothers Corporate Finance in 2000. |  Steve Martin BSc (Hons) MRPharmS, Commercial Development DirectorSteve Martin was appointed Director of Pharmaceuticals of BioProgress plc in November 2005, with broad experience in commercial development and marketing of pharmaceutical and healthcare products. He was appointed to the Board of BioProgress plc on 25 July 2006. Prior to this appointment he was the founder and Chief Executive Officer of Vienna Healthcare, a business advising on commercial strategy within the global speciality pharmaceutical markets. Previously he founded and ran the Stevenden Healthcare Group; a UK based speciality pharmaceutical company, owned a small chain of community pharmacies and sat on a number of professional and advisory health committees. He has also developed a number of innovative pharmaceutical products including a number of first-to-market generic products and co-founded a specialist clinical research organisation in the area of topical and transdermal medicines. He is a registered and practising pharmacist and began his career with Paydens, a family-run retail pharmacy and distribution company. |
Contact details
Milton Road
Cambridge CB4 0FQ
United Kingdom
Tel: +44 (0)1223 394250
Fax: +44 (0)1223 394251
